Boston Scientific Announces FDA Approval and U.S. Launch of EPIC Vascular Stent
Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration approval and market launch of the Epic™ Vascular Self-Expanding Stent System. The Epic Stent is designed to open blocked arteries in patients with iliac artery stenosis, a form of peripheral vascular disease associated with severe leg pain caused by insufficient blood flow.
"The Epic Stent System demonstrates an excellent combination of flexibility, radial force and deployment accuracy - all important attributes when treating challenging atherosclerotic lesions in the iliac arteries," said Thomas Shimshak, M.D., medical director at Wheaton Franciscan Heart Care in Racine, WI. "The comprehensive stent size matrix should also help meet a variety of clinical requirements when treating iliac arterial disease with no compromise in deliverability or stent performance."
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.